PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.
Analyze analyst forecasts for the company and compare them with competitors.
180.25K
No peer data available for comparison.
-36.05K
No peer data available for comparison.
-2.06
No peer data available for comparison.
-62.22M
No peer data available for comparison.
-36.05K
No peer data available for comparison.
6.68M
No peer data available for comparison.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
-50.53%
Worse than EXEL's revenue growth rate of 8.96%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than EXEL's ebitda margin of 18.96%.
No Data
No DCF data available for this metric in the selected year.
-20.00%
Worse than EXEL's ebit margin of 17.71%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
100.00%
Better than EXEL's cash as percentage of revenue of 84.73%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than EXEL's receivables as percentage of revenue of 14.92%.
No Data
No DCF data available for this metric in the selected year.
40.00%
Worse than EXEL's inventories as percentage of revenue of 1.68%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Worse than EXEL's payables as percentage of revenue of 1.83%.
No Data
No DCF data available for this metric in the selected year.
-29.43%
Better than EXEL's capex as percentage of revenue of -5.27%.
4.99%
Better than EXEL's weighted average cost of capital (wacc) of 6.62%.
5.02%
Better than EXEL's cost of equity of 6.67%.
4.08%
Better than EXEL's cost of debt of 4.26%.
-0.23
Better than EXEL's beta of 0.51.
30.07M
Better than EXEL's diluted shares outstanding of 321.46M.
1.57M
Better than EXEL's total debt of 189.94M.
49.31M
Worse than EXEL's total equity of 11.10B.
50.89M
Worse than EXEL's total capital of 11.29B.
3.09%
Worse than EXEL's debt weighting of 1.68%.
96.91%
Worse than EXEL's equity weighting of 98.32%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
2.00%
Worse than EXEL's long-term growth rate of 4.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than EXEL's net debt of -73.05M.
71.33M
Worse than EXEL's equity value of 8.24B.
2.37
Worse than EXEL's equity value per share of 25.62.